CollPlant Biotechnologies (CLGN) Restructuring Costs (2018 - 2019)
CollPlant Biotechnologies (CLGN) reported Restructuring Costs of $323000.0 for Q3 2019, down 37.64% on a YoY basis from $518000.0 in Q3 2018, and up 9.86% quarter-over-quarter from $294000.0 in Q2 2019.
CollPlant Biotechnologies (CLGN) Restructuring Costs (2018 - 2019) Analysis & Trends
CollPlant Biotechnologies has reported Restructuring Costs for 2 years, with the latest figure at $323000.0 in Q3 2019.
- For the quarter ending Q3 2019, Restructuring Costs fell 37.64% year-over-year to $323000.0; the trailing twelve-month figure through Sep 2019 stood at $323000.0 (down 37.64% YoY), and the FY2020 full-year result was $228000.0, down 6.17% from the prior year.
- Restructuring Costs for Q3 2019 stood at $323000.0, up from $294000.0 in the prior quarter.
- The five-year high for Restructuring Costs was $1.9 million in Q1 2018, with the low at $294000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 323,000.00 |
| Jun 30, 2019 | 294,000.00 |
| Mar 31, 2019 | 493,000.00 |
| Dec 31, 2018 | 334,000.00 |
| Sep 30, 2018 | 518,000.00 |
| Jun 30, 2018 | 587,000.00 |
| Mar 31, 2018 | 1.95 Mn |